Variants with the highest potential for clinical relevance include a variant that is protective for lung cancer, two risk-factor variants (lung cancer and cutaneous malignant melanoma), 5 pathogenic noncoding SNVs (acute myeloid leukemia [AML] with maturation), a pathogenic intronic SNV in EHBP1 associated with hereditary prostate cancer, and 16 drug-response variants that affect the dosage, efficacy, toxicity/adverse drug reaction or response to various cancer drugs. This evidence concerns the gene EHBP1 and lung carcinoma.